17

Allied Biotech Corporation

1780 · TWO · Healthcare / Drug Manufacturers - Specialty & Generic

23.50TWD-0.20 (-0.84%)

Price History

Full chart

Market Stats

Previous Close23.70
Open23.50
Day Range23.00 – 23.60
52-Week Range16.31 – 35.46
Volume15.00K
Market Cap2.77B
P/E (TTM)14.16
Forward P/E0.00
EPS1.79
Dividend Yield4.95%
Beta0.20
50-Day Avg24.36
200-Day Avg26.28

About

Allied Biotech Corporation engages in the manufacture and sale of carotenoids worldwide. The company's products include Beta-Carotene that offers yellow to reddish orange shades to appeal color in various applications; Beta-Apo-8'-Carotenal, which is used as a food colorant, and provides a range of orange to red shades; and Lycopene, which offers a range of red shades as a nutrient for food, dietary supplements, and pharmaceutical products. It also provides Canthaxanthin, which offers a range of shades of reddish orange for food and beverage applications; Lutein, a carotenoid that provides a range of green leafed vegetables, such as spinach, kale, broccoli, and egg yolks.; and Nano Coenzyme Q10, an antioxidant, which is used in the transformation of energy in the body. It serves food, beverage, dietary supplement, and feed industries. The company was founded in 2001 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Qing Hui Lin
  • HeadquartersNo. 71, Tun Hua South Road, Taipei, Taiwan, 106045, Taiwan
  • Websitehttps://www.altratene.com

Leadership

  • Mr. Qing Hui LinCEO & Director
  • Mr. Bin YangChief Operating Officer
  • Xinghui YangAccounting Supervisor

Financials

Income Statement

Currency: TWD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue283.13M359.52M389.94M429.03M421.47M478.91M479.57M474.46M524.11M573.63M681.73M765.26M639.39M618.07M676.76M716.75M720.43M806.92M849.51M
Growth (%)-+26.98%+8.46%+10.02%-1.76%+13.63%+0.14%-1.07%+10.46%+9.45%+18.85%+12.25%-16.45%-3.34%+9.50%+5.91%+0.51%+12.00%+5.28%
Cost of Revenue221.28M242.36M256.98M291.32M283.93M308.01M337.95M310.93M329.03M354.31M449.31M464.00M365.02M376.91M418.71M445.70M473.99M548.53M540.90M
Gross Profit61.85M117.16M132.96M137.71M137.53M170.90M141.63M163.54M195.08M219.32M232.43M301.27M-241.15M258.05M271.05M246.44M258.38M308.61M
Gross Margin21.84%32.59%34.10%32.10%32.63%35.69%29.53%34.47%37.22%38.23%34.09%39.37%-39.02%38.13%37.82%34.21%32.02%36.33%
Operating Expense76.27M94.28M106.70M106.13M118.97M118.59M139.89M150.32M143.75M155.64M142.57M155.87M-138.59M229.22M169.26M157.72M170.27M188.22M
Operating Income-14.43M22.88M26.25M31.58M18.56M52.31M1.74M13.22M51.34M63.67M89.85M145.39M136.51M102.57M28.82M101.78M88.71M88.11M120.39M
Operating Margin-5.10%6.36%6.73%7.36%4.40%10.92%0.36%2.79%9.79%11.10%13.18%19.00%21.35%16.59%4.26%14.20%12.31%10.92%14.17%
EBITDA4.42M57.68M59.17M51.80M57.10M84.62M50.20M59.77M106.39M104.30M142.50M222.92M199.14M173.32M94.06M270.55M204.79M205.93M242.44M
EBITDA Margin1.56%16.04%15.17%12.07%13.55%17.67%10.47%12.60%20.30%18.18%20.90%29.13%31.14%28.04%13.90%37.75%28.43%25.52%28.54%
Net Income-44.01M2.70M4.06M64.00K15.29M39.61M6.36M7.01M46.34M40.23M71.03M133.48M106.90M79.47M13.04M146.74M97.41M100.94M129.46M
Net Income Margin-15.54%0.75%1.04%0.01%3.63%8.27%1.33%1.48%8.84%7.01%10.42%17.44%16.72%12.86%1.93%20.47%13.52%12.51%15.24%
R&D27.40M23.59M22.95M18.72M20.38M21.85M24.49M26.15M27.53M22.70M28.37M24.96M24.34M24.57M25.74M24.56M26.09M26.12M28.43M
R&D as % of Total Revenue9.68%6.56%5.88%4.36%4.83%4.56%5.11%5.51%5.25%3.96%4.16%3.26%3.81%3.97%3.80%3.43%3.62%3.24%3.35%
Interest Expense16.55M20.40M16.64M10.90M5.92M5.79M4.10M5.96M6.03M5.35M5.18M5.54M6.51M9.00M11.25M11.75M12.96M13.96M17.32M
Interest Expense % of Total Revenue5.85%5.68%4.27%2.54%1.40%1.21%0.85%1.26%1.15%0.93%0.76%0.72%1.02%1.46%1.66%1.64%1.80%1.73%2.04%

Balance Sheet

Currency: TWD2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets------------1.95B2.26B2.44B2.18B2.08B2.26B2.09B
Total Liabilities------------791.06M1.12B1.36B999.40M910.12M1.06B857.19M
Total Equity------------1.16B1.15B1.08B1.18B1.17B1.20B1.23B
Cash------------408.79M703.48M757.39M679.75M618.49M978.33M789.08M
Total Debt------------687.60M1.00B1.25B838.04M796.61M955.38M-
Net Debt------------278.81M299.38M490.08M158.29M178.11M-22.95M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-59.48M72.43M164.27M137.62M223.79M217.13M
Investing Cash Flow-33.84M-180.94M219.02M-40.94M70.55M-
Financing Cash Flow-200.67M164.24M-462.00M-158.33M64.94M-
Capital Expenditure056.82M49.99M54.66M47.91M26.81M33.58M
Free Cash Flow-2.66M22.44M109.62M89.71M196.98M183.55M
Dividends Paid-94.89M76.12M47.68M114.46M81.42M96.02M
FCF to OCF-4.47%30.98%66.73%65.19%88.02%84.53%
Dividend Paid to FCF-3572.67%339.22%43.49%127.59%41.33%52.32%

Key Statistics & Ratios

Market Cap2.77B
Enterprise Value2.25B
Trailing P/E14.16
Forward P/E0.00
Price / Sales3.00
Price / Book1.79
EPS1.79
Book Value13.90
Revenue (TTM)922.49M
Gross Profit (TTM)356.24M
EBITDA190.42M
Profit Margin19.57%
Operating Margin17.47%
Return on Equity13.72%
Return on Assets3.46%
Shares Outstanding109.08M
Shares Float67.89M
Beta0.20
Dividend Yield4.95%
Dividend Rate1.25
Payout Ratio125.85%

Dividends

20261×
1.25Jun 4, 2026
20251×
1.00Jul 17, 2025
20241×
0.85Jul 18, 2024
20231×
1.20Jul 13, 2023
20221×
0.50Jul 6, 2022
20211×
0.80Sep 1, 2021
20201×
1.00Jul 16, 2020
20191×
1.00Jul 15, 2019
20181×
0.66Aug 15, 2018
20171×
0.45Jul 6, 2017
20161×
0.40Jul 1, 2016